Drug Profile
Research programme: monoclonal antibodies - Surface Oncology/Vaccinex
Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Vaccinex
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Sep 2023 Surface Oncology has been acquired by Coherus BioSciences
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 08 Jan 2018 Vaccinex and Surface Oncology enter into a research collaboration and option license agreement to develop monoclonal antibodies